<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640834</url>
  </required_header>
  <id_info>
    <org_study_id>14576</org_study_id>
    <secondary_id>I1R-MC-GLBR</secondary_id>
    <secondary_id>2011-006178-19</secondary_id>
    <nct_id>NCT01640834</nct_id>
  </id_info>
  <brief_title>Study of LY2409021 in Participants With Type 1 Diabetes</brief_title>
  <official_title>Pilot Study of the Effects of LY2409021 in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves taking a single dose of 100 milligrams (mg) or 300 mg LY2409021 or
      placebo (an inactive medicine) taken as up to 3 capsules by mouth. The study will evaluate if
      this drug will reduce the amount of insulin a type 1 diabetic needs over 24 hours. This study
      includes a 7-day hospitalization period at the clinical research unit (CRU) and will involve
      screening within 30 days of the start of the study as well as telephone consultations within
      5 days after discharge from the CRU.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose</measure>
    <time_frame>Baseline (Day 1), Day 2</time_frame>
    <description>The mean absolute change in total insulin dose over 24 hours (Day 2, 24-hour insulin dose - Day 1, 24-hour insulin dose) is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Percentage Change From Baseline to Day 2 in 24-hour Insulin</measure>
    <time_frame>Baseline (Day 1), Day 2</time_frame>
    <description>The percentage change in total insulin dose over 24 hours (Day 2, 24-hour insulin dose - Day 1, 24-hour insulin dose) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021</measure>
    <time_frame>Predose (Day 2) through 120 hours postdose (Day 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021</measure>
    <time_frame>Predose (Day 2) through 120 hours postdose (Day 7)</time_frame>
    <description>Exposure in terms of AUC of LY2409021 from time 0 extrapolated to infinity (AUCinf) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Change From Baseline in 24 Hour Insulin Dose During Drug Washout Period</measure>
    <time_frame>Baseline (Day 1), Day 3 up to Day 6</time_frame>
    <description>Data were not captured, and, therefore, this outcome measure was not analyzed. Zero participants were included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Change From Baseline in 24 Hour Insulin Dose Needed to Maintain Euglycemia</measure>
    <time_frame>Baseline (Day 1), Day 3 up to Day 6</time_frame>
    <description>Data were not captured, and, therefore, this outcome measure was not analyzed. Zero participants were included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Maximum Concentration (Cmax) of Glucose Concentration After 1 Milligram (mg) Glucagon Injection on Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>The Cmax of glucose following a single dose of glucagon (1 mg) administered via an intramuscular injection is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Area Under the Glucose Concentration Curve After a Single Dose of Glucagon on Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Area under the glucose concentration curve from time 0 through 2 hours after a single dose of glucagon (1 milligram) administered via an intramuscular injection is reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>100 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 3 capsules administered as a single oral dose on Day 2.
Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2409021</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>100 mg LY2409021</arm_group_label>
    <arm_group_label>300 mg LY2409021</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>100 mg LY2409021</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Administered via intramuscular injection</description>
    <arm_group_label>100 mg LY2409021</arm_group_label>
    <arm_group_label>300 mg LY2409021</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have had type 1 diabetes mellitus (T1DM) based on the World Health Organization
             classification for at least 1 year and have a daily insulin dose ≤1.5 international
             units (IU) per kilogram (kg) of body weight

          -  Have a glycated hemoglobin A1c (HbA1c) of no greater than 9.0% as measured at
             screening

          -  Have a body mass index (BMI) ≥19.0 and ≤35.0 kilograms per meter squared (kg/m^2)

          -  Have given written informed consent approved by Lilly

        Exclusion Criteria:

          -  Received any oral or injectable medication intended for the treatment of diabetes
             mellitus other than insulins in the 3 months prior to screening

          -  Have had more than 1 episode of severe hypoglycemia within 3 months prior to entry
             into the study, or are currently diagnosed as having hypoglycemia unawareness

          -  Are pregnant or intend to become pregnant during the course of the study

          -  Women who are breastfeeding

          -  Have a history of stroke, myocardial infarction, heart failure, unstable angina, or a
             coronary revascularization procedure within 6 months of screening

          -  Have fasting triglycerides &gt;500 milligrams per deciliter (mg/dL) (5.65 millimoles per
             liter [mmol/L])

          -  Have obvious clinical signs, symptoms, or laboratory evidence of liver disease
             (alanine transaminase [ALT] or aspartate transaminase [AST] greater than 2 times the
             upper limit of normal at screening)

          -  Have a history of renal transplantation or are currently receiving renal dialysis or
             have a screening creatinine &gt;2.0 mg/dL (177 micromoles per liter [μmol/L])

          -  Have had any other disease, illness, or condition (including known diabetic autonomic
             neuropathy, drug or alcohol abuse, or psychiatric disorder) within the 6 months prior
             to screening that precludes the participant from following and completing the study or
             could increase their risk for hypoglycemia, according to the investigator's judgment

          -  Are currently enrolled in, have completed, or have discontinued within the last 30
             days from a clinical trial involving an off-label use of an investigational drug or
             device, or are concurrently enrolled in any other type of medical research judged not
             to be scientifically or medically compatible with this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <results_first_submitted>March 24, 2018</results_first_submitted>
  <results_first_submitted_qc>March 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2018</results_first_posted>
  <last_update_submitted>March 24, 2018</last_update_submitted>
  <last_update_submitted_qc>March 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>100 mg LY2409021</title>
          <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
        </group>
        <group group_id="P2">
          <title>300 mg LY2409021</title>
          <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: 3 capsules administered as a single oral dose on Day 2.
Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>100 mg LY2409021</title>
          <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
        </group>
        <group group_id="B2">
          <title>300 mg LY2409021</title>
          <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: 3 capsules administered as a single oral dose on Day 2.
Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="12.8"/>
                    <measurement group_id="B2" value="47.1" spread="5.7"/>
                    <measurement group_id="B3" value="43.3" spread="10.6"/>
                    <measurement group_id="B4" value="43.0" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose</title>
        <description>The mean absolute change in total insulin dose over 24 hours (Day 2, 24-hour insulin dose - Day 1, 24-hour insulin dose) is reported.</description>
        <time_frame>Baseline (Day 1), Day 2</time_frame>
        <population>All participants who received a dose of LY2409021 or placebo and had evaluable 24-hour insulin data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg LY2409021</title>
            <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O2">
            <title>300 mg LY2409021</title>
            <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: 3 capsules administered as a single oral dose on Day 2.
Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose</title>
          <description>The mean absolute change in total insulin dose over 24 hours (Day 2, 24-hour insulin dose - Day 1, 24-hour insulin dose) is reported.</description>
          <population>All participants who received a dose of LY2409021 or placebo and had evaluable 24-hour insulin data.</population>
          <units>insulin units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="7.15"/>
                    <measurement group_id="O2" value="0.80" spread="9.63"/>
                    <measurement group_id="O3" value="7.69" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The mean change on Day 2 from Day 1 in the 24-hour insulin dose for the placebo group was subtracted from each participant's change on Day 2 from Day 1 in the 24-hour insulin dose. This placebo adjusted 24-hour insulin dose was compared within the 100-mg LY2409021 dose group using a 1 sample t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0542</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.82</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The mean change on Day 2 from Day 1 in the 24-hour insulin dose for the placebo group was subtracted from each participant's change on Day 2 from Day 1 in the 24-hour insulin dose. This placebo adjusted 24-hour insulin dose was compared within the 300-mg LY2409021 dose group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0826</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.95</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Percentage Change From Baseline to Day 2 in 24-hour Insulin</title>
        <description>The percentage change in total insulin dose over 24 hours (Day 2, 24-hour insulin dose - Day 1, 24-hour insulin dose) is reported.</description>
        <time_frame>Baseline (Day 1), Day 2</time_frame>
        <population>All participants who received a dose of LY2409021 or placebo and had evaluable 24-hour insulin data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg LY2409021</title>
            <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O2">
            <title>300 mg LY2409021</title>
            <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: 3 capsules administered as a single oral dose on Day 2.
Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Percentage Change From Baseline to Day 2 in 24-hour Insulin</title>
          <description>The percentage change in total insulin dose over 24 hours (Day 2, 24-hour insulin dose - Day 1, 24-hour insulin dose) is reported.</description>
          <population>All participants who received a dose of LY2409021 or placebo and had evaluable 24-hour insulin data.</population>
          <units>percentage of insulin units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="19.90"/>
                    <measurement group_id="O2" value="3.12" spread="18.34"/>
                    <measurement group_id="O3" value="22.75" spread="22.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using the percent change in insulin dose, which takes into account absolute differences in individual insulin doses. The mean percent change on Day 2 from Day 1 in the 24-hour insulin dose for the placebo group was subtracted from each participant's percent change on Day 2 from Day 1 in the 24-hour insulin dose. This placebo adjusted 24-hour insulin dose was compared within the 100-mg LY2409021 dose group using a 1 sample t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0460</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-17.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.7</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using the percent change in insulin dose, which takes into account absolute differences in individual insulin doses. The mean percent change on Day 2 from Day 1 in the 24-hour insulin dose for the placebo group was subtracted from each participant's percent change on Day 2 from Day 1 in the 24-hour insulin dose. This placebo adjusted 24-hour insulin dose was compared within the 300-mg LY2409021 dose group using a 1 sample t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0192</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-19.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.0</ci_lower_limit>
            <ci_upper_limit>-4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021</title>
        <time_frame>Predose (Day 2) through 120 hours postdose (Day 7)</time_frame>
        <population>All participants who received a dose of LY2409021 and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg LY2409021</title>
            <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O2">
            <title>300 mg LY2409021</title>
            <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021</title>
          <population>All participants who received a dose of LY2409021 and had evaluable pharmacokinetic data.</population>
          <units>nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2620" spread="23"/>
                    <measurement group_id="O2" value="6090" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021</title>
        <description>Exposure in terms of AUC of LY2409021 from time 0 extrapolated to infinity (AUCinf) is reported.</description>
        <time_frame>Predose (Day 2) through 120 hours postdose (Day 7)</time_frame>
        <population>All participants who received a dose of LY2409021 and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg LY2409021</title>
            <description>LY2409021: 100 milligrams (mg), capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O2">
            <title>300 mg LY2409021</title>
            <description>LY2409021: 300 milligrams (mg), capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021</title>
          <description>Exposure in terms of AUC of LY2409021 from time 0 extrapolated to infinity (AUCinf) is reported.</description>
          <population>All participants who received a dose of LY2409021 and had evaluable pharmacokinetic data.</population>
          <units>nanograms * hours per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209000" spread="30"/>
                    <measurement group_id="O2" value="506000" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Change From Baseline in 24 Hour Insulin Dose During Drug Washout Period</title>
        <description>Data were not captured, and, therefore, this outcome measure was not analyzed. Zero participants were included in the analysis.</description>
        <time_frame>Baseline (Day 1), Day 3 up to Day 6</time_frame>
        <population>This outcome measure was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg LY2409021</title>
            <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O2">
            <title>300 mg LY2409021</title>
            <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: 3 capsules administered as a single oral dose on Day 2.
Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Change From Baseline in 24 Hour Insulin Dose During Drug Washout Period</title>
          <description>Data were not captured, and, therefore, this outcome measure was not analyzed. Zero participants were included in the analysis.</description>
          <population>This outcome measure was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Change From Baseline in 24 Hour Insulin Dose Needed to Maintain Euglycemia</title>
        <description>Data were not captured, and, therefore, this outcome measure was not analyzed. Zero participants were included in the analysis.</description>
        <time_frame>Baseline (Day 1), Day 3 up to Day 6</time_frame>
        <population>This outcome measure was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg LY2409021</title>
            <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O2">
            <title>300 mg LY2409021</title>
            <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: 3 capsules administered as a single oral dose on Day 2.
Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Change From Baseline in 24 Hour Insulin Dose Needed to Maintain Euglycemia</title>
          <description>Data were not captured, and, therefore, this outcome measure was not analyzed. Zero participants were included in the analysis.</description>
          <population>This outcome measure was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Maximum Concentration (Cmax) of Glucose Concentration After 1 Milligram (mg) Glucagon Injection on Day 3</title>
        <description>The Cmax of glucose following a single dose of glucagon (1 mg) administered via an intramuscular injection is reported.</description>
        <time_frame>Day 3</time_frame>
        <population>All participants who received a dose of LY2409021 or placebo and had evaluable post-glucagon injection glucose concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg LY2409021</title>
            <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O2">
            <title>300 mg LY2409021</title>
            <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: 3 capsules administered as a single oral dose on Day 2.
Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Maximum Concentration (Cmax) of Glucose Concentration After 1 Milligram (mg) Glucagon Injection on Day 3</title>
          <description>The Cmax of glucose following a single dose of glucagon (1 mg) administered via an intramuscular injection is reported.</description>
          <population>All participants who received a dose of LY2409021 or placebo and had evaluable post-glucagon injection glucose concentration data.</population>
          <units>milligrams per deciliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.9" spread="19"/>
                    <measurement group_id="O2" value="141.3" spread="19"/>
                    <measurement group_id="O3" value="201.8" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the effect of LY2409021 treatment on peak glucose concentration after an intramuscular injection of glucagon (1 milligram).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0187</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-82</ci_lower_limit>
            <ci_upper_limit>-9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the effect of LY2409021 treatment on peak glucose concentration after an intramuscular injection of glucagon (1 milligram).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-96</ci_lower_limit>
            <ci_upper_limit>-23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Area Under the Glucose Concentration Curve After a Single Dose of Glucagon on Day 3</title>
        <description>Area under the glucose concentration curve from time 0 through 2 hours after a single dose of glucagon (1 milligram) administered via an intramuscular injection is reported.</description>
        <time_frame>Day 3</time_frame>
        <population>All participants who received a dose of LY2409021 or placebo and had evaluable post-glucagon injection glucose concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg LY2409021</title>
            <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O2">
            <title>300 mg LY2409021</title>
            <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: 3 capsules administered as a single oral dose on Day 2.
Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Area Under the Glucose Concentration Curve After a Single Dose of Glucagon on Day 3</title>
          <description>Area under the glucose concentration curve from time 0 through 2 hours after a single dose of glucagon (1 milligram) administered via an intramuscular injection is reported.</description>
          <population>All participants who received a dose of LY2409021 or placebo and had evaluable post-glucagon injection glucose concentration data.</population>
          <units>milligrams * minutes per deciliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15534.3" spread="21"/>
                    <measurement group_id="O2" value="14885.5" spread="16"/>
                    <measurement group_id="O3" value="20189.7" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the effect of LY2409021 treatment on area under the glucose concentration curve from time 0 to 2 hours postdose following an intramuscular injection of glucagon (1 milligram).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0278</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4423</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8256</ci_lower_limit>
            <ci_upper_limit>-590</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the effect of LY2409021 treatment on area under the glucose concentration curve from time 0 to 2 hours postdose following an intramuscular injection of glucagon (1 milligram).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5187</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8371</ci_lower_limit>
            <ci_upper_limit>-2004</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>100 mg LY2409021</title>
          <description>LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
Placebo: 2 capsules, administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
        </group>
        <group group_id="E2">
          <title>300 mg LY2409021</title>
          <description>LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
Glucagon: 1 mg administered via intramuscular injection on Day 3.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: 3 capsules administered as a single oral dose on Day 2.
Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

